| 2.535 0.085 (3.47%) | 11-29 11:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.03  |
1-year : | 3.54 |
| Resists | First : | 2.59 |
Second : | 3.03 |
| Pivot price | 2.26 |
|||
| Supports | First : | 2.1 |
Second : | 1.8 |
| MAs | MA(5) : | 2.45 |
MA(20) : | 2.2 |
| MA(100) : | 2.42 |
MA(250) : | 2.09 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 89.4  |
D(3) : | 91.3 |
| RSI | RSI(14): 67.1 |
|||
| 52-week | High : | 3.16 | Low : | 1.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LAB ] has closed below upper band by 10.1%. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.55 - 2.56 | 2.56 - 2.57 |
| Low: | 2.4 - 2.42 | 2.42 - 2.43 |
| Close: | 2.43 - 2.45 | 2.45 - 2.47 |
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Thu, 09 Nov 2023
SomaLogic tops Wall Street estimates as merger looms – BizWest - BizWest
Thu, 09 Nov 2023
Standard Biotools Inc (LAB) is higher by 1.99% in a Week, Should You Hold? - InvestorsObserver
Wed, 08 Nov 2023
Standard BioTools Inc. (NASDAQ:LAB) Q3 2023 Earnings Call Transcript - Yahoo Finance
Thu, 02 Nov 2023
Standard BioTools to Present at the Jefferies London Healthcare Conference - Yahoo Finance
Wed, 25 Oct 2023
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023 - Yahoo Finance
Thu, 05 Oct 2023
Standard BioTools Inc.'s (NASDAQ:LAB) institutional investors lost 27% last week but have benefitted from longer-term gains - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Diagnostics & Research
|
|
| Shares Out | 79 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 61.6 (%) |
| Shares Short | 3,390 (K) |
| Shares Short P.Month | 3,520 (K) |
| EPS | -0.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | -72 % |
| Operating Margin | -29.5 % |
| Return on Assets (ttm) | -12.9 % |
| Return on Equity (ttm) | -35.4 % |
| Qtrly Rev. Growth | -14.2 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 1.32 |
| EBITDA (p.s.) | -0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -2.67 |
| PEG Ratio | 0 |
| Price to Book value | 2.06 |
| Price to Sales | 1.91 |
| Price to Cash Flow | -4.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|